On July 24, 2019, the World Bank announced that it had debarred a business unit of Merck Sharp & Dohme B.V. (MSD B.V.), a Dutch subsidiary of the U.S. publicly traded pharmaceutical company Merck & Co. According to the facts of the case, the MSD B.V. business unit, which successfully bid on a contract to supply contraceptives for a health systems improvement project in Bangladesh, failed to disclose the full commission amount its predecessor company had agreed to pay its local agent. The debarment is for a reduced period of twelve months as a result of MSD B.V.’s cooperation and voluntary remedial actions.
July 24, 2019
World Bank imposes 12-month debarment for fraudulent practices in connection with a Bangladeshi health development program
Related by Topic
New Post
DOJ issues declination with disgorgement letter to Boston Consulting Group for possible FCPA offenses
August 29, 2024
News Alert
New Post
Former oil and gas trader pleads guilty to additional FCPA charges
August 23, 2024
News Alert
New Post
One of ten co-conspirators pleads guilty for role in U.S. sanctions evasion scheme
August 22, 2024
News Alert